People and Business News — 3/22
People News
Seqster PDM, Inc. announced the appointment of Bruno Villetelle, to its strategic advisory board.
Curebase has named Dr. Aaron Kamauu and Dr. Amir Lahav to the Curebase Advisory Board.
NNIT has appointed Camilla G. Møhl as its new SVP and Chief People, Communications and Marketing Officer.
ClinOne has named Andrea Valente as Chief Executive Officer.
Advanced Clinical announced that Dr. Andreas Amrein has joined the Executive Team as Senior Vice President of Asia-Pacific and Japan, as well as Managing Director for Europe and Canada.
MMS Holdings announced this week the addition of Dr. Robert Allen as Principal Medical Director to its Global Drug Safety and Pharmacovigilance team.
Total Diversity Clinical Trial Management announced Mark Hanley as a Board Member and Advisor.
Business News
Florence Healthcare announced that 285 million Americans now live within 25-miles of a Florence digital-workflow-equipped clinical research site.
Calyx announced its electronic data capture system has been selected by a leading pharmaceutical company to capture Real World Evidence data for a global, late-phase study.
Rho announced that it has been named the Autoimmune Diseases Statistical and Clinical Coordinating Center for the National Institute of Allergy and Infectious Diseases.
Suvoda LLC launched a refreshed brand, to better reflect its leadership position as a global clinical trial technology company that specializes in highly complex studies, such as oncology, central nervous system, and rare disease.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
